Novozymes Biopharma will announce a new development in animal-free supplements for industrial cell culture at the Bioprocess International Conference and Exhibition 2008.
Novozymes Biopharma, specialists in large scale recombinant protein production for the biopharmaceutical industry, has unveiled the first product under the Cell Prime brand.
The Transferrin recombinant supplement is commercially ready in scalable manufacturing quantities for consistency of supply.
Designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers, Novozyme said that this advance will improve the consistency and productivity of an industrial cell culture process.
Novozymes Biopharma will also exhibit its two key product lines, Recombumin and LongR3 IGF-I.
Recombumin is a yeast-derived recombinant human albumin, which has a structure identical to human serum albumin (HSA).
It is the only animal-free recombinant human albumin approved for use in the manufacture of human therapeutics.
LongR3 IGF-I is an analogue of human insulin-like growth factor I (IGF-I) specifically engineered by Novozymes Biopharma for use in industrial cell culture.
It provides improved performance and a consistent, compliant and animal-free alternative to recombinant insulin.
The technical conference will also include a poster display on advances in animal-free media supplements for optimal cell culture performance, presented by Sally Grosvenor, senior scientist and scientific communications manager, Novozymes Biopharma.
A workshop, entitled 'Cell Culture and Processing Track' will be also be hosted by Grosvenor, on 25 September.
Novozymes Biopharma will be found on booth 219 at Bioprocess International Conference and Exhibition, 23-26 September, Disneyland Hotel, Anaheim, California.
